Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
BioMimetix logo — Late-stage company supported by robust clinical results with...

BioMimetix

Late-stage company supported by robust clinical results with a Drug Class: Redox-Active Metalloporphyrins

Founded 2013 United States Greenwood Village, United States 10 employees Seed Total: $2.00M Biotechnology, Pharmaceutical

General Information

Company Name BioMimetix
Founded Year 2013
Location United States Greenwood Village, United States
Employees 10
Industries Biotechnology, Pharmaceutical
Funding Stage Seed
Business Model B2B, B2B2C, Platform
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with BioMimetix. To contact BioMimetix, visit biomimetixpharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BioMimetix compare?

A PDF of BioMimetix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BioMimetix soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BioMimetix

BioMimetix, founded in 2013, is a biotechnology firm based in the United States, dedicated to innovating cancer treatment through its unique compound, BMX-001. Positioned in the Biotechnology and Pharmaceutical industries, the company specializes in Redox-Active Metalloporphyrins, showcasing the potential to redefine therapeutic approaches in oncology.

BioMimetix's focus on creating transformative solutions is grounded in robust clinical results, highlighting its capacity to significantly impact cancer therapy. Despite its pioneering approach, the company appears underfunded, having last received a $2.00M Seed Round investment in 2011 without listed investor names. This gap suggests potential capital requirements to bridge its innovative ambitions with market readiness.

Overall, BioMimetix's strength lies in its scientific advancements, representing a promising opportunity for investors aiming to support leading-edge cancer treatments.

Business keywords: Biomimetix, Redox-Active Metalloporphyrins, Cancer Treatment, Clinical Research, Radiation Oncology, Oncology, Chemotherapy, Clinical Trials, High Grade Glioma, Head and Neck Cancer, Anal Cancer, Rectal Cancer, NCI Grants

Services & Products

Development of redox-active metalloporphyrins for cancer treatment
Conducting Phase 3 clinical trials
Providing innovative oncology solutions

Target Customers

Cancer patients Oncology healthcare providers Clinics and hospitals specializing in cancer treatment

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed $2.00M -
01 Jul 2011
Spinout Undisclosed 1
Cornell University
01 Jan 2011

BioMimetix Alternatives & Competitors

View All Alternatives
BioMimetix vs
Apollomics
Apollomics United States

We are a biopharmaceutical company committed to the discovery and development of mono- and combinati...

Post-IPO Equity
26 employees
Biotechnology, Health Care
BioMimetix vs
MimiVax, Inc.
MimiVax, Inc. United States

Disrupting Cancer with Immunotherapy

Venture round
3 employees
Biopharma, Biotechnology
BioMimetix vs
Cytimmune Sciences
Cytimmune Sciences United States

Developing safer more effective therapies that can attack tumors on multiple fronts simultaneously.

Venture round
6 employees
Biotechnology, Health Care
View all alternatives

FAQ About BioMimetix

Late-stage company supported by robust clinical results with a Drug Class: Redox-Active Metalloporphyrins
BioMimetix was founded in 2013.
BioMimetix is headquartered in Greenwood Village, United States.
BioMimetix operates in Biotechnology and Pharmaceutical. Its work centres on Biomimetix, Redox-Active Metalloporphyrins, Cancer Treatment and Clinical Research. Its customers include Cancer patients, Oncology healthcare providers and Clinics and hospitals specializing in cancer treatment.
BioMimetix has a B2B, B2B2C and Platform business model. Its revenue comes from Product Sales and Licensing.
BioMimetix has approximately 10 employees.
BioMimetix has completed 2 funding rounds, raising a total of $2.00M. The latest funding stage is Seed.
BioMimetix offers: Development of redox-active metalloporphyrins for cancer treatment, Conducting Phase 3 clinical trials, Providing innovative oncology solutions.
Top alternatives and competitors to BioMimetix include Apollomics, MimiVax, Inc., Cytimmune Sciences, Geron Corporation, Sitka Biopharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BioMimetix and Apollomics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BioMimetix, https://bouncewatch.com/company/biomimetix, updated 19 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes